Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.54 |
| ▸ | CA4 | P22748 | 4/20 | 0.54 |
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA6 | P23280 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28030420 | 0.87 | CA2 (0.57) | CA2CA4CA1CA6TSHR | |
| SCHEMBL28870388 | 0.81 | CA2 (0.67) | CA2CA4CA1CA6TSHR | |
| SCHEMBL7213113 | 0.78 | CA2 (0.50) | CA2CA4TSHRAPOBEC3AHTT | |
| SCHEMBL17388711 | 0.77 | CA2 (0.50) | CA2CA4CA1CA6TSHR | |
| SCHEMBL9109330 | 0.76 | TUBB1 (0.47) | CA2CA4CA1CA6TSHR | |
| SCHEMBL5236856 | 0.76 | TUBB1 (0.58) | CA2CA4CA1TSHRAPOBEC3A | |
| SCHEMBL1729022 | 0.76 | MAPT (0.48) | CA2CA4CA1CA6TSHR | |
| SCHEMBL28426250 | 0.75 | CA2 (0.58) | CA2CA4CA1CA6TSHR | |
| SCHEMBL27631190 | 0.74 | ACHE (0.50) | CA2CA4CA1CA6TSHR | |
| SCHEMBL9352550 | 0.74 | ACHE (0.50) | CA2CA4CA1CA6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618102-B1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | LILLY CO ELI (US) | 2010-02-10 | — | — | EP | disclosed |
| US-7279499-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| US-20060199858-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-09-07 | — | — | US | disclosed |
| EP-1618102-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004094401-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199858-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | GPER1, ESR2, ESR1 | CA2 2077/4885CA4 2826/4885CA1 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.